2018-10-02T18:13:48-05:00 2017-12-31 814234542 BPM LLP 10 ALMADEN BOULEVARD SUITE 1000 SAN JOSE CA 951132238 990 2017-01-01 204284925 QUANTUM LEAP HEALTHCARE COLLABORATIVE QUAN 8558660505 3450 CALIFORNIA STREET SAN FRANCISCO CA 941181837 DAVE MANDELKERN CEO 8558660505 2018-09-27 1 MICHAEL STEPHEN SCHAFFER P00210063 4089616300 2018-09-27 108.72.126.167 2018-09-27 17:26:34 PD P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 FD6251F6FB7123D4B026EB6814EBA84C6E349BAE 2017 2018-06-14 16:35:46Z DAVE MANDELKERN 3450 CALIFORNIA STREET SAN FRANCISCO CA 941181837 12489295 0 X WWW.QUANTUMLEAPHEALTH.ORG X 2005 CA THE MISSION OF QUANTUM LEAP HEALTHCARE COLLABORATIVE IS TO PROVIDE MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT. 8 6 11 6 0 0 1285937 3033157 10154959 9456138 0 0 0 0 11440896 12489295 172 0 0 0 1036880 1663809 39688 118500 181879 7200929 8819449 8277669 10601758 3163227 1887537 8443360 11141939 10538106 11349148 -2094746 -207209 X THE MISSION OF QUANTUM LEAP HEALTHCARE COLLABORATIVE IS TO PROVIDE MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT. 0 0 8021265 9269540 I-SPY 2 (INVESTIGATION OF SERIAL STUDIES TO PREDICT YOUR THERAPEUTIC RESPONSE WITH IMAGING AND MOLECULAR ANALYSIS 2) IS A CLINICAL TRIAL FOR WOMEN WITH NEW DIAGNOSED LOCALLY ADVANCED BREAST CANCER. THE TRIAL TESTS WHETHER ADDING INVESTIGATIONAL DRUGS TO STANDARD CHEMOTHERAPY IS BETTER THAN STANDARD CHEMOTHERAPY ALONE BEFORE HAVING SURGERY. THE TREATMENT PHASE OF THIS TRIAL TESTS MULTIPLE INVESTIGATIONAL DRUGS THAT ARE THOUGHT TO TARGET THE BIOLOGY OF EACH PARTICIPANT'S TUMOR. QUANTUM LEAP HAS MADE SIGNIFICANT FINANCIAL INVESTMENT IN THIS IMPORTANT TRIAL, AS A CO-PROJECT MANAGER, AND CONTINUES TO ADAPT THE DESIGN TO IMPROVE THE QUALITY OF THE DATA OBTAINED. QUANTUM IS EXPLORING ADDITIONAL PROCESSES TO ALLOW PATIENTS WHO HAVE NOT RESPONDED TO ONE DRUG TO PARTICIPATE IN THE TRIAL FOR OTHER INVESTIGATIONAL DRUGS UNDER STUDY THAT MAY PROVE BENEFICIAL TO THE PATIENT. 478605 CALM (COLLABORATORY FOR ACCELERATING LEARNING IN MEDICINE) IS A PROJECT TO TRANSFORM THE PRACTICE OF MEDICINE. USING A HOLISTIC APPROACH, THE PROJECT LOOKS TO ALIGN THE PROCESSES OF CLINICAL CARE AND RESEARCH BY INTEGRATING INFORMATION AND WORKFLOW PROCESSES TO ACCELERATE DECISION-MAKING THROUGH A PROVIDER PORTAL. THE PROJECT AIMS TO CHANGE HOW FUTURE LEADERS IN MEDICINE ARE EDUCATED, AS WELL AS DEVELOP POLICIES AND REIMBURSEMENT MECHANISMS THAT SUPPORT INTEGRATED MEDICAL CARE AND BETTER OUTCOMES. QUANTUM LEAP IS UTILIZING THE ONESOURCE DATA PLATFORM TO SUPPORT THE PROVIDER PORTAL THROUGH ELECTRONIC DATA CAPTURE, WITH THE INTENT TO CREATE INTERACTIVE HEALTH CARE MANAGEMENT SYSTEMS THAT PROVIDE COMPREHENSIVE INFORMATION FOR IMPROVED HEALTH CARE AND ALLOW PATIENTS TO REPORT OUTCOMES TO FULLY INTEGRATE THE LEARNING EXPERIENCE. QUANTUM LEAP IS WORKING WITH RESEARCH AND EDUCATIONAL INSTITUTIONS, AS WELL AS COMMERCIAL ENTITIES, IN THIS PROCESS 470481 23200 BCTMATCH: BREASTCANCERTRIALS.ORG IS AN ONLINE SERVICE THAT HELPS PATIENTS FIND BREAST CANCER TRIALS PERSONALIZED TO THEIR SITUATION BY MATCHING THEIR HISTORIES TO TRIAL ELIGIBILITY CRITERIA. BCTMATCH IS A CUSTOMIZABLE, TECHNOLOGY PLATFORM THAT SUPPORTS CLINICAL TRIAL MATCHING ACROSS ALL CANCERS. THE BOSTON VETERAN'S ADMINISTRATION MEDICAL CENTER IS USING BCTMATCH TO SUPPORT ITS LUNG CANCER CLINICAL TRIAL MATCHING APPLICATION. 590812 163398 ATHENA NETWORK (WWW.ATHENANETWORK.ORG) IS A VERY LARGE, MULTI-STATE PROJECT WITHIN THE UNIVERSITY OF CALIFORNIA. ATHENA'S MISSION IS TO TRACK UP TO 150,000 WOMEN WITH BREAST CANCER OVER A LONG PERIOD OF TIME TO FIND GENETIC MARKERS FOR BREAST CANCER. QUANTUM LEAP HAS BEEN PROVIDING PROJECT MANAGEMENT AND TECHNOLOGY EXPERTISE TO ATHENA SINCE ITS INCEPTION.I-SPY 1 NETWORK UTILIZES I-SPY CLINICAL TRIAL METHODOLOGY TO BRING NEW PHARMACEUTICAL AGENTS INTO THE SYSTEM, ASSURING THAT THEY MEET SAFETY QUALIFICATIONS FOR FURTHER TESTING IN THE PHASE 2 AND 3 TRIALS IN A MORE EFFICIENT AND EFFECTIVE MANNER.I-SPY 3 IS INTENDED TO BE A PHASE 3 CLINICAL TRIAL TO CONTINUE TO TEST WHETHER ADDING INVESTIGATIONAL DRUGS TO STANDARD CHEMOTHERAPY IS BETTER THAN STANDARD CHEMOTHERAPY ALONE BEFORE HAVING SURGERY. 590812 163398 9561163 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 31 0 11 1 0 0 0 0 0 0 0 0 0 0 X 8 6 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 0 1 1 0 CA X X THE ORGANIZATION 8558660505 3450 CALIFORNIA STREET SAN FRANCISCO CA 941181837 DAVID MANDELKERN CEO 24.00 X X 222482 0 0 LUCAS DEBREED DIRECTOR 0.50 X 0 0 0 BOB PATTERSON CHAIR 0.50 X X 0 0 0 LAURA ESSERMAN DIRECTOR 20.00 X 0 0 0 ROBYN RUTLEDGE SECRETARY 2.00 X X 95000 0 0 JEFF PFEFFER DIRECTOR 0.50 X 0 0 0 SUE FOLEY TREASURER 0.50 X X 0 0 0 ANNA BARKER DIRECTOR 0.50 X 0 0 0 ADAM ASARE CHIEF DATA OFFICER 40.00 X 213404 0 11770 MICHAEL RESENDEZ SENIOR SOFTWARE ENGINEER 40.00 X 148873 0 26103 NANCY LISSER DIRECTOR OF LEGAL AFFAIRS 40.00 X 152741 0 32426 THOMAS BECHTOLD IT ARCHITECT 40.00 X 167798 0 315 MICHAEL BANKERT DIRECTOR OF FINANCE 40.00 X 157718 0 10273 1158016 0 80887 6 0 1 0 CCS ASSOCIATES 1420 SPRING HILL ROAD SUITE 355 MCLEAN VA 22102 CLINICAL TRIALS RESEARCH ORGANIZATION 639585 DAVID MANDELKERN PO BOX 19564 STANFORD CA 94309 ORGANIZATIONAL OPERATIONS MANAGEMENT 222482 HORNTHAL & CO 2234 BEACH STREET SAN FRANCISCO CA 94123 PUBLIC RELATIONS AND FUNDRAISING 138000 KAREN KIMURA 3400 LOWER LOCK AVENUE BELMONT CA 94002 SOFTWARE DEVELOPMENT PROJECT MANAGEMENT 123159 BLUE PATH HEALTH INC 929 SIR FRANCIS DRAKE BLVD SUITE KENTFIELD CA 94904 HEALTHCARE STRATEGY AND IT IMPLEMENTATIO 110000 7 3033157 3033157 SPECIALIZED PROGRAMMING 541511 9447198 9447198 CONSULTING AND RESEARCH CONTRACTS 541511 8940 8940 9456138 12489295 9456138 0 0 317482 257412 53396 6674 1157091 871106 258270 27715 5713 5713 107776 85202 22574 75747 54590 19118 2039 89907 5865 81705 2337 73830 73830 118500 118500 855314 592528 256287 6499 27900 20859 7041 79480 58592 20888 197387 169569 19171 8647 3041 2242 799 27269 4297 22972 PROGRAM MANAGEMENT 3800005 3800005 RESEARCH SITES 3497733 3497733 RESEARCH 125400 125400 PAYROLL SERVICE FEES 24966 15498 9468 17217 15763 1454 10601758 9561163 858716 181879 6452955 7158858 18000 1040000 1849035 2803472 61309 52742 26061 6874 3321 19187 58740 67680 8443360 11141939 9328106 9719148 1210000 1630000 10538106 11349148 X -3236099 -3541952 1141353 3334743 -2094746 -207209 8443360 11141939 1887537 0 X 0 1 X 1 0 X 6252298 266491 808721 1285937 3033157 11646604 6252298 266491 808721 1285937 3033157 11646604 9110926 2535678 81 299 199 579 11647183 29859221 0.21770 0.22860 X THE QUANTUM LEAP HEALTHCARE COLLABORATIVE BELIEVES THAT IT SATISFIES THE FACTS AND CIRCUMSTANCES TEST AND QUALIFIES AS A PUBLIC CHARITY. THE ORGANIZATION HAS AN ESTABLISHED RECORD OF RECEIVING PUBLIC SUPPORT, AND HAS MET ITS EXEMPT PURPOSE BY PROVIDING SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS. THE ORGANIZATION HAS PLANS TO INCREASE ITS PUBLIC SUPPORT PERCENTAGE THROUGH INCREASED RESOURCES DEDICATED TO FUND DEVELOPMENT ACTIVITIES. 26061 6874 19187 19187 X PART X, LINE 2: QUANTUM LEAP IS EXEMPT FROM FEDERAL AND STATE INCOME TAXES UNDER THE PROVISIONS OF SECTION 501(C)(3) AND SECTION 170(B)(1)(A)(VI) OF THE INTERNAL REVENUE CODE AND CORRESPONDING PROVISIONS OF THE CALIFORNIA REVENUE AND TAXATION CODE. ACCORDINGLY, NO PROVISION FOR INCOME TAXES HAS BEEN MADE IN THE ACCOMPANYING FINANCIAL STATEMENTS. QUANTUM LEAP MAY BE SUBJECT TO UNRELATED BUSINESS INCOME TAX. X X 1 HORNTHAL & CO 2234 BEACH STREET SAN FRANCISCO CA 94123 DONOR SOLICITATIONS 0 2200000 118500 2081500 2200000 118500 2081500 CA X 0 0 0 0 0 0 0 0 0 DAVID MANDELKERN CEO 222482 0 0 0 0 0 0 0 0 0 222482 0 0 0 ADAM ASARE CHIEF DATA OFFICER 213404 0 0 0 0 0 0 0 11770 0 225174 0 0 0 MICHAEL RESENDEZ SENIOR SOFTWARE ENGINEER 148873 0 0 0 0 0 0 0 26103 0 174976 0 0 0 NANCY LISSER DIRECTOR OF LEGAL AFFAIRS 152741 0 0 0 0 0 0 0 32426 0 185167 0 0 0 THOMAS BECHTOLD IT ARCHITECT 167798 0 0 0 0 0 0 0 315 0 168113 0 0 0 MICHAEL BANKERT DIRECTOR OF FINANCE 157718 0 0 0 0 0 0 0 10273 0 167991 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS PREPARED BY AN INDEPENDENT CPA FIRM IN CONJUNCTION WITH THE ORGANIZATION'S DIRECTOR OF FINANCE. A DRAFT OF FORM 990 IS REVIEWED BY THE DIRECTOR OF FINANCE, AND CORRECTIONS/MODIFICATIONS ARE MADE BY THE OUTSIDE CPA. THE REVISED DRAFT IS THEN REVIEWED BY THE DIRECTOR OF FINANCE. ANY CONCERNS ARE RAISED WITH THE CPA FIRM AND A CONSENSUS IS ACHIEVED. BOARD MEMBERS ARE SENT A COPY OF THE TAX RETURN PRIOR TO FILING FOR THEIR REVIEW. THE RETURN IS THEN FINALIZED AND ELECTRONICALLY FILED WITH THE TAXING AUTHORITIES. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY IS PRESENTED AND REVIEWED ANNUALLY. EACH BOARD MEMBER IS REQUIRED TO ACKNOWLEDGE IN WRITING THAT NO CONFLICT EXISTS. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF THE PRESIDENT OF THE ORGANIZATION WAS DETERMINED AND APPROVED BY VOTE OF THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS. PERSONNEL OF UCSF REVIEWED JOB REQUIREMENTS AGAINST TECHICAL ABILITIES OF SUBCONTRACTORS AND DETERMINED WHETHER OR NOT THEY MATCHED. ALL SUBCONTRACTORS WERE ENGAGED AT BELOW-MARKET RATES. FORM 990, PART VI, SECTION C, LINE 19 ALL GOVERNING DOCUMENTS, AUDITED FINANCIAL STATEMENTS AND FORM 990, RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX, ARE PROVIDED UPON WRITTEN REQUEST THROUGH THE QUANTUM LEAP HEALTHCARE WEBSITE. CENTER FOR CLINICAL INNOVATION DBA ENCOMPASS HEALTH FOUNDATION 320 FAIRWAY DRIVE HALF MOON BAY CA 94019 461637647 FUNDING CLINICAL RESEARCH AND INITIATIVES CA 501(C)(3) LINE 7 QUANTUMLEAP HEALTHCARE COLLABORATIVE 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0